Wednesday, October 14, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 12, 2026

Netskope outlines $870M–$876M fiscal 2027 revenue target as AI-native platform drives product expansion

View original at seekingalpha.com
Netskope outlines $870M–$876M fiscal 2027 revenue target as AI-native platform drives product expansion Earnings Call Insights: Netskope (NTSK) Q4 2026 MANAGEMENT VIEW * CEO Sanjay Beri opened by highlighting, "We ended the year on a high note with results that exceeded our guidance across all key metrics." He reported…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Q1 fiscal 2027 revenue expected in range of $197 million to $199 million, representing approximately 26% growth at midpoint

    60% confidence
  • Fiscal 2027 operating margin expected at approximately negative 10%, gradually improving from negative 16% in first half

    60% confidence
  • 56% of customers were using 4 or more Netskope One products and 27% were using 6 or more products as of the end of Q4

    60% confidence
  • 56% of Netskope customers were using 4 or more Netskope One products and 27% were using 6 or more products as of end of Q4

    60% confidence
  • 116% net retention rate is viewed as very strong, though NRR varies quarter-to-quarter

    60% confidence
  • Every conversation I have, people come to us and say they already run all their AI traffic through Netskope

    60% confidence
  • Netskope is building sales rep funnel for next year with fully ramped reps coming online in the second half of the year

    60% confidence
  • Netskope delivered revenue of $709 million or 32% growth; ARR of $811 million, up 31% year-over-year; net new ARR of $193 million, up 35% versus fiscal 2025; operating margin improvement of 18 percentage points; and generated $12 million in positive free cash flow

    60% confidence
  • Netskope's win rate is over 80% if they get to a POC

    60% confidence
  • Netskope achieved its first year of positive free cash flow with $12 million

    60% confidence
  • All new AI products are charged by transaction (prompt and response) rather than seat-based

    60% confidence
  • Management expects negative free cash flow of $50 million to $60 million in Q1 due to annual billings transition, returning to positive in the second half of the year

    60% confidence
  • Path to sustainable positive free cash flow is not expected to be linear

    60% confidence
  • Most organizations are in the infancy of AI adoption, in the first inning, with 90% of their AI usage being shadow AI

    60% confidence
  • Fiscal 2027 free cash flow margin expected in range of 2% to 4%

    60% confidence
  • All of the new products released are charged by transaction, where a transaction is a prompt and a response

    60% confidence
  • The agentic era will expose networks that were built in the public cloud where you're going to get way worse performance

    60% confidence
  • Guidance reflects macroeconomic risk and geopolitical headwinds

    60% confidence
  • Netskope views 116% NRR as very strong and NRR does vary quarter-to-quarter

    60% confidence
  • Q1 fiscal 2027 expected to have negative free cash flow of $50 million to $60 million due to annual billings transition

    60% confidence
  • AI enablement has moved up in importance with customers saying they already run all AI traffic through Netskope

    60% confidence
  • Fiscal 2027 gross margin expected at approximately 77%

    60% confidence
  • For Q1 fiscal 2027, Netskope expects revenue in the range of $197 million to $199 million, representing growth of approximately 26% at the midpoint

    60% confidence
  • Most impact from sales rep investments to operating margin expected in first half of fiscal 2027

    60% confidence
  • Netskope has a library of more than 190 proprietary, purpose-built, specialized AI models

    60% confidence
  • Netskope delivered operating margin improvement of 18 percentage points while continuing to invest in innovation and go-to-market

    60% confidence
  • Most organizations are in the infancy stage with AI, in the first inning, with 90% of AI usage being shadow AI

    60% confidence
  • Netskope has a library of more than 190 proprietary, purpose-built, specialized AI models

    60% confidence
  • Netskope generated $12 million in free cash flow for fiscal year 2026, marking the company's first ever year of positive free cash flow

    60% confidence
  • The agentic era will expose networks built in public cloud with worse performance

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com